Stocks and Investing Stocks and Investing
Fri, March 10, 2023

Chris Howerton Downgraded (BTAI) to Hold and Increased Target to $22 on, Mar 10th, 2023


Published on 2024-10-28 02:13:34 - WOPRAI, Chris Howerton
  Print publication without navigation


Chris Howerton of Jefferies, Downgraded "BioXcel Therapeutics, Inc." (BTAI) to Hold and Increased Target from $20 to $22 on, Mar 10th, 2023.

Chris has made no other calls on BTAI in the last 4 months.



There are 5 other peers that have a rating on BTAI. Out of the 5 peers that are also analyzing BTAI, 1 agrees with Chris's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Corinne Jenkins of "Goldman Sachs" Maintained at Hold with Increased Target to $26 on, Thursday, January 26th, 2023


These are the ratings of the 4 analyists that currently disagree with Chris


  • Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $79 on, Monday, February 27th, 2023
  • Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Increased Target to $38 on, Wednesday, February 8th, 2023
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $76 on, Friday, November 11th, 2022
  • Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Decreased Target to $25 on, Friday, November 11th, 2022
Contributing Sources